Amgen (TSX:AMGN) Accounts Payable: C$4,021 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:AMGN Amgen Inc TSX:AMGN
70 GF Score
Price C$30.97
GF Value C$26.95
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Amgen Accounts Payable?

Amgen TSX:AMGN +0.91% 70 Accounts Payable is C$4,021 Mil as of Jun. 2026. GuruFocus rates TSX:AMGN with a GF Score™ of 70/100 and a GF Value™ of C$26.95 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Amgen's Accounts Payable for the quarter that ended in Jun. 2026 was C$4,021 Mil.

Amgen's quarterly Accounts Payable increased from Dec. 2025 (C$3,265 Mil) to Mar. 2026 (C$4,027 Mil) but then declined from Mar. 2026 (C$4,027 Mil) to Jun. 2026 (C$4,021 Mil).

Amgen's annual Accounts Payable increased from Dec. 2023 (C$2,133 Mil) to Dec. 2024 (C$2,718 Mil) and increased from Dec. 2024 (C$2,718 Mil) to Dec. 2025 (C$3,265 Mil).

Amgen Accounts Payable Historical Data

* Premium members only.

The historical data trend for Amgen's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Accounts Payable Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,748.48 2,135.56 2,133.14 2,718.33 3,265.28

Amgen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,114.07 3,926.09 3,265.28 4,026.82 4,020.74
TSX:AMGN
70GF Score
Amgen Inc TSX:AMGN
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of C$4,021 Mil mean?
Amgen (TSX:AMGN) has a Accounts Payable of C$4,021 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Amgen and its competitors.
Is Amgen's Accounts Payable too high?
Amgen's current Accounts Payable is C$4,021 Mil. Overall, Amgen has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Accounts Payable compare to GILD and PFE?
Amgen's Accounts Payable of C$4,021 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Amgen and its competitors. Amgen's current Accounts Payable is C$4,021 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (TSX:AMGN) is currently considered Modestly Overvalued. The stock's GF Value™ is C$26.95, compared to a current price of C$30.97 — trading 14.9% above its estimated fair value. The current Accounts Payable is C$4,021 Mil. Amgen's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Amgen (TSX:AMGN), the current Accounts Payable is C$4,021 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (TSX:AMGN) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of C$30.97 is trading 14.9% above its estimated GF Value™ of C$26.95. GuruFocus considers Amgen to be Modestly Overvalued.

Key valuation signals for TSX:AMGN:

  • Accounts Payable: C$4,021 Mil
  • GF Value™: C$26.95 vs. price of C$30.97 (14.9% above fair value)
  • GF Score™: 70/100 with 8 warning signs

No single metric tells the full story. See the TSX:AMGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
70GF Score

Get the complete analysis for TSX:AMGN

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$30.97
Price
C$26.95
GF Value